Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

QNRX vs ILAG: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

QNRX Wins Head-to-Head Institutional Verdict (2–1 across 6 Pillars · 5–3 Matrix Metrics)

QNRX Overall Winner 6-Pillar Tally: QNRX 2 – 1 ILAG (3 Tie) Matrix Metrics: QNRX 5 – 3 ILAG

As of Nov 20, 2026, Quoin Pharmaceuticals, Ltd. (QNRX) is the stronger overall head-to-head candidate over Intelligent Living Application Group Inc. (ILAG) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). QNRX carries a Unified Composite Score of 46.1/100 (HOLD) at $3.28 (N/M Forward P/E, 0.0% operating margin), whereas ILAG carries 49.6/100 (HOLD) at $1.53 (N/M Forward P/E, -279.6% operating margin).

  • Composite vs. Pillar Nuance: While ILAG currently prints a higher short-term Unified Composite Score (49.6/100 HOLD vs. QNRX 46.1/100 HOLD), QNRX captures the overall institutional head-to-head verdict (5–3 matrix metrics and 2–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -279.6% operating margin) and revenue trajectory (+0.0% vs. +2.3% YoY).
  • Technical & Structure Timing Caution: QNRX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.5); meanwhile ILAG is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About QNRX vs ILAG
QNRX NASDAQ Head-to-Head Winner
Quoin Pharmaceuticals, Ltd. American Depositary Shares
Pharmaceutical Preparations
$3.28
-2.35% 1D
Market Cap $16.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.34β · 74% Vol
Unified Composite Score
46.1 / 100 HOLD
Tech 38.0 Fund 47.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.8%), weak momentum, RSI 32
RSI-14: 32.5 · SMA20: $3.81 · SMA50: $4.64
ILAG NASDAQ
Intelligent Living Application Group Inc. Ordinary Shares
Partitions, Shelvg, Lockers, & Of Fice & Store Fixtures
$1.53
-16.85% 1D
Market Cap $3.3M
TTM Revenue $4.5M
Forward P/E N/M
Beta / 30D Vol 0.81β · 94% Vol
Unified Composite Score
49.6 / 100 HOLD
Tech 38.0 Fund 69.0 Flow 50.0 Mom 45.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.8%), weak momentum, RSI 32
RSI-14: 32.2 · SMA20: $1.93 · SMA50: $2.50

6-Pillar Scorecard Institutional Category Breakdown (QNRX 2 – 1 ILAG)

Columns: Metric · QNRX · ILAG
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E 7.6x N/M
PEG Ratio N/M N/M
EV / Revenue N/M 0.7x
2. Growth & Scale ILAG
Revenue Growth (YoY) +0.0% +2.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $4.5M
Market Cap $16.1M $3.3M
3. Profitability & Quality QNRX
Gross Margin N/A 1.2%
Operating Margin 0.0% -279.6%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -142.6% -215.3%
4. Balance Sheet & Cash Flow QNRX
Cash Generation (TTM) N/A -$12M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $5.97 Book/Sh · -142.6% ROE $1.66 Book/Sh · -215.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew Thin ADR Chain Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Building Products & Equipment Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: QNRX (5) vs ILAG (3)
Institutional Metric QNRX ILAG Criterion Row Edge
Market Capitalization
Scale
$16.1M $3.3M Larger Scale QNRX
Trailing P/E Ratio
Valuation
7.6x N/M Lower Multiple QNRX
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +2.3% Higher Growth ILAG
Operating Margin (TTM)
Profitability
0.0% -279.6% Higher Margin QNRX
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-142.6% -215.3% Higher ROE QNRX
52-Week Range Position
Momentum
0% ($3–$24) 18% ($0–$7) Stronger Trend ILAG
Beta / 30D Volatility
Risk Regime
1.34β · 74% Vol 0.81β · 94% Vol Lower Realized Risk QNRX
Unified Institutional Score
Composite Signal
46.1 / 100 (HOLD) 49.6 / 100 (HOLD) Higher Composite ILAG
Trailing 12M Revenue (USD)
Operating Scale
N/A $4.5M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 1.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 0.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($5.97 Book/Sh · -142.6% ROE) -$12M EBITDA ($1.66 Book/Sh · -215.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon QNRX +19.25 pp
QNRX: -17.79% · ILAG: -37.04%
3M Horizon QNRX +26.18 pp
QNRX: -24.94% · ILAG: -51.12%
6M Horizon QNRX +15.07 pp
QNRX: -45.7% · ILAG: -60.77%
1Y Horizon ILAG +295.48 pp
QNRX: -81.96% · ILAG: +213.52%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on QNRX vs ILAG. Trailing 12-month operating profitability (QNRX 0.0% vs ILAG -279.6%) and valuation multiples (QNRX N/M vs ILAG N/M Forward P/E) are benchmarked directly in Pillar 4 below.

QNRX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-142.6% · N/M
ILAG ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.5M
Gross Margin1.2%
Op. Margin-279.6%
ROE / Fwd P/E-215.3% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
QNRX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact QNRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ILAG UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ILAG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
QNRX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $16.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ILAG Moat Profile Cyclical / Execution-Driven Positioning
Building Products & Equipment Operator
Competes within the Building Products & Equipment value chain with $3.3M market capitalization and -279.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ QNRX vs ILAG Key Questions & Quantitative Answers

As of Nov 20, 2026, Quoin Pharmaceuticals, Ltd. (QNRX) is the stronger overall head-to-head candidate over Intelligent Living Application Group Inc. (ILAG) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). QNRX carries a Unified Composite Score of 46.1/100 (HOLD) at $3.28 (N/M Forward P/E, 0.0% operating margin), whereas ILAG carries 49.6/100 (HOLD) at $1.53 (N/M Forward P/E, -279.6% operating margin). Composite vs. Pillar Nuance: While ILAG currently prints a higher short-term Unified Composite Score (49.6/100 HOLD vs. QNRX 46.1/100 HOLD), QNRX captures the overall institutional head-to-head verdict (5–3 matrix metrics and 2–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -279.6% operating margin) and revenue trajectory (+0.0% vs. +2.3% YoY). Technical & Structure Timing Caution: QNRX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.5); meanwhile ILAG is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ILAG leads the Growth & Scale pillar: QNRX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ILAG at +2.3% YoY revenue growth and +0.0% YoY earnings growth on $4.5M TTM revenue (1.2% gross margin, -279.6% operating margin). On trailing 12-month operating scale, QNRX generates N/A in USD-normalized revenue versus $4.5M for ILAG. In operating R&D and SG&A reinvestment, QNRX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ILAG.

QNRX and ILAG trade at balanced relative valuation multiples. QNRX trades at N/M Forward P/E, 7.6x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ILAG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.7x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against QNRX (-142.6% ROE) versus ILAG (-215.3% ROE) capital efficiency.

In options market volatility and institutional positioning, QNRX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.34β · 74% Vol realized risk). By comparison, ILAG carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.81β · 94% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.